News Page
Published November 18, 2025
Baxter sold a promise of safer care and a flagship pump that would power years of growth. Best in class. Seamless launch. Investors believed. Here is what the complaint says really happened. April 1, 2024: FDA clears Baxter’s Novum IQ pump for the U.S. market. Executives call it a landmark and say the rollout is going great.
April 7, 2025: a hospital whistleblower warns the pumps are not safe. April 24: Baxter sends a letter about underinfusion risks. June 6: the FDA flags the issue, class one severity. July 14: Baxter discloses about 79 serious injuries and two deaths tied to the pump, and adds overinfusion and non delivery concerns. July 22: another FDA notice follows.
July 31: Baxter pauses all new Novum sales. The stock falls about 22% in a day. Confidence evaporates.
If you bought shares during this period, you may have been misled. Now, more investors are joining the lawsuit.